PMID- 34483901
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211101
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 12
DP  - 2021
TI  - The Extract of Sonneratia apetala Leaves and Branches Ameliorates Hyperuricemia 
      in Mice by Regulating Renal Uric Acid Transporters and Suppressing the Activation 
      of the JAK/STAT Signaling Pathway.
PG  - 698219
LID - 10.3389/fphar.2021.698219 [doi]
LID - 698219
AB  - Sonneratia apetala Buch-Ham., an exotic mangrove species with antidiabetic, 
      antibacterial, and antioxidant capacities, mainly distributes in the southeast 
      coastal areas in China. The present work investigated the protective effects of 
      Sonneratia apetala leaves and branches extraction (SAL) on hyperuricemia (HUA) in 
      mice. Potassium oxonate (PO) and hypoxanthine (HX) were used to establish the HUA 
      model by challenge for consecutive 7 days. Results revealed that SAL inhibited 
      the increases in kidney weight and index compared to the vehicle group. 
      Meanwhile, SAL significantly decreased the levels of uric acid (UA), creatinine 
      (CRE), and blood urea nitrogen (BUN) in serum. Additionally, SAL inhibited the 
      activity of xanthine oxidase (XOD) in the liver. SAL ameliorated PO- and 
      HX-induced histopathological changes. Moreover, it regulated oxidative stress 
      markers including malondialdehyde (MDA), catalase (CAT), superoxide dismutase 
      (SOD) activity, and glutathione (GSH) content. Also, SAL inhibited the increases 
      in renal levels of interleukin-6 (IL-6), interleukin-18 (IL-18), interleukin-1beta 
      (IL-1beta), tumor necrosis factor (TNF-alpha), monocyte chemotactic protein 1 (MCP-1), 
      and transforming growth factor-beta (TGF-beta). SAL remarkably reduced suppressor of 
      cytokine signaling 3 (SOCS3), Janus kinase 2 (JAK2), and subsequent 
      phosphorylation of signal transducer and activator of transcription 3 (STAT3) 
      expression. In addition, SAL inhibited the activation of nuclear factor kappa-B 
      (NF-kappaB) in the kidney. Furthermore, SAL protected against HUA by regulating renal 
      UA transporters of organic anion transporter (OAT1), urate reabsorption 
      transporter 1 (URAT1), and glucose transporter 9 (GLUT9). These findings 
      suggested that SAL ameliorated HUA by inhibiting the production of uric acid and 
      enhancing renal urate excretion, which are related to oxidative stress and 
      inflammation, and the possible molecular mechanisms include its ability to 
      inhibit the JAK/STAT signaling pathway. Thus, SAL might be developed into a 
      promising agent for HUA treatments.
CI  - Copyright (c) 2021 Wu, Chen, Jiang, Wu, Liu, Gao, Wu, Yi, Su, Cai and Chen.
FAU - Wu, Yu-Lin
AU  - Wu YL
AD  - Guangdong Provincial Key Laboratory of New Drug Development and Research of 
      Chinese Medicine, School of Pharmaceutical Sciences, Guangzhou University of 
      Chinese Medicine, Guangzhou, China.
FAU - Chen, Jin-Fen
AU  - Chen JF
AD  - Guangdong Provincial Key Laboratory of New Drug Development and Research of 
      Chinese Medicine, School of Pharmaceutical Sciences, Guangzhou University of 
      Chinese Medicine, Guangzhou, China.
FAU - Jiang, Lin-Yun
AU  - Jiang LY
AD  - The First Affiliated Hospital of Chinese Medicine, Guangzhou University of 
      Chinese Medicine, Guangzhou, China.
FAU - Wu, Xiao-Li
AU  - Wu XL
AD  - School of Biomedical and Pharmaceutical Sciences, Guangdong University of 
      Technology, Guangzhou, China.
FAU - Liu, Yu-Hong
AU  - Liu YH
AD  - Guangdong Provincial Key Laboratory of New Drug Development and Research of 
      Chinese Medicine, School of Pharmaceutical Sciences, Guangzhou University of 
      Chinese Medicine, Guangzhou, China.
FAU - Gao, Chang-Jun
AU  - Gao CJ
AD  - Guangdong Academy of Forestry, Guangzhou, China.
AD  - Guangdong Provincial Key Laboratory of Silviculture, Protection and Utilization, 
      Guangzhou, China.
FAU - Wu, Yan
AU  - Wu Y
AD  - Guangdong Academy of Forestry, Guangzhou, China.
FAU - Yi, Xiao-Qing
AU  - Yi XQ
AD  - Guangdong Academy of Forestry, Guangzhou, China.
FAU - Su, Zi-Ren
AU  - Su ZR
AD  - Guangdong Provincial Key Laboratory of New Drug Development and Research of 
      Chinese Medicine, School of Pharmaceutical Sciences, Guangzhou University of 
      Chinese Medicine, Guangzhou, China.
FAU - Cai, Jian
AU  - Cai J
AD  - Guangdong Academy of Forestry, Guangzhou, China.
AD  - Guangdong Provincial Key Laboratory of Silviculture, Protection and Utilization, 
      Guangzhou, China.
FAU - Chen, Jian-Nan
AU  - Chen JN
AD  - Guangdong Provincial Key Laboratory of New Drug Development and Research of 
      Chinese Medicine, School of Pharmaceutical Sciences, Guangzhou University of 
      Chinese Medicine, Guangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20210816
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
EIN - Front Pharmacol. 2021 Oct 15;12:760098. PMID: 34721044
PMC - PMC8415165
OTO - NOTNLM
OT  - JAK/STAT pathway
OT  - Sonneratia apetala leaves and branches
OT  - hyperuricemia
OT  - oxidative stress
OT  - renal uric acid transporters
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/09/07 06:00
MHDA- 2021/09/07 06:01
PMCR- 2021/08/16
CRDT- 2021/09/06 05:54
PHST- 2021/04/22 00:00 [received]
PHST- 2021/07/05 00:00 [accepted]
PHST- 2021/09/06 05:54 [entrez]
PHST- 2021/09/07 06:00 [pubmed]
PHST- 2021/09/07 06:01 [medline]
PHST- 2021/08/16 00:00 [pmc-release]
AID - 698219 [pii]
AID - 10.3389/fphar.2021.698219 [doi]
PST - epublish
SO  - Front Pharmacol. 2021 Aug 16;12:698219. doi: 10.3389/fphar.2021.698219. 
      eCollection 2021.